CCNE1 Amplification Confers Poor Outcomes and Therapeutic Resistance in Breast Cancer

PURPOSE: Recent evidence suggests cyclin E1 (CCNE1) amplification as a potential novel therapeutic target. The clinical significance of CCNE1 amplification in breast cancer remains poorly defined. This study explores the clinicogenomic characteristics of CCNE1-amplified breast cancer. EXPERIMENTAL DESIGN: We analyzed genomic and clinical data from patients included in the MSK Breast Translational database who underwent targeted sequencing between January 2014 and October 2025. Allele-specific copy number, including CCNE1 amplification, was assessed by FACETS. RESULTS: Out of 6,318 breast cancers, 251 (4.0%) had CCNE1 amplification. The prevalence of CCNE1 amplification was lower in HR+/HER2- (2.1%) compared to HER2+ (6.7%) and triple-negative breast cancers (8.7%, P<2.2x10-16). CCNE1 amplification was associated with aggressive clinicopathological features across all receptor subtypes. HR+/HER2- tumors harboring CCNE1 amplification had higher tumor grade (77.1% vs 57.1%, P=8.3x10-04), lack of progesterone receptor expression (27.0% vs 15.2%, P=8.8x10-03) and a higher prevalence of estrogen-receptor low expression (ER ≤10%, 25.4% vs 6.5%, P=8.4x10-07). CCNE1-amplified breast cancers were associated with TP53 alterations, high fraction of genome altered, and whole genome doubling events, reflecting marked chromosomal instability. CCNE1 amplification was associated with significantly shorter PFS on first-line THP in HER2+ subtype (8.4 vs 18.0 months, HR 2.33, 95%CI 1.31-4.12, P=3.8×10⁻³), and non-significant trends toward shorter PFS in HR+/HER2- (HR 1.49, 95%CI 0.86-2.58, P=0.16) and triple-negative cancers (HR 1.43, 95%CI 0.95-2.15, P=0.084). CONCLUSIONS: CCNE1 amplification defines a subset of breast cancer characterized by high genomic instability and poor clinical outcomes, supporting its role as a potential biomarker for novel therapeutic strategies in this clinical context.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-11-17
DOI
https://doi.org/10.1158/1078-0432.ccr-26-2631
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CCNE1 Amplification Confers Poor Outcomes and Therapeutic Resistance in Breast Cancer

Giuseppe Curigliano, Pier Selenica, Pedram Razavi, Anton Mikhailovich Safonov et al.
2 links
Clinical Cancer Research
Breast Cancer Treatment Studies
article

CCNE1 Amplification Confers Poor Outcomes and Therapeutic Resistance in Breast Cancer

Giuseppe Curigliano, Pier Selenica, Pedram Razavi, Anton Mikhailovich Safonov, Andrea M. Gazzo, Britta Weigelt, Sarat Chandarlapaty, Mark E. Robson, Luca Boscolo Bielo, Jorge Sergio Reis-Filho, Ezra Y. Rosen, Alison M. Schram, Antonio Marra, Yingjie Zhu, Dara S. Ross
article en

Abstract

PURPOSE: Recent evidence suggests cyclin E1 (CCNE1) amplification as a potential novel therapeutic target. The clinical significance of CCNE1 amplification in breast cancer remains poorly defined. This study explores the clinicogenomic characteristics of CCNE1-amplified breast cancer. EXPERIMENTAL DESIGN: We analyzed genomic and clinical data from patients included in the MSK Breast Translational database who underwent targeted sequencing between January 2014 and October 2025. Allele-specific copy number, including CCNE1 amplification, was assessed by FACETS. RESULTS: Out of 6,318 breast cancers, 251 (4.0%) had CCNE1 amplification. The prevalence of CCNE1 amplification was lower in HR+/HER2- (2.1%) compared to HER2+ (6.7%) and triple-negative breast cancers (8.7%, P<2.2x10-16). CCNE1 amplification was associated with aggressive clinicopathological features across all receptor subtypes. HR+/HER2- tumors harboring CCNE1 amplification had higher tumor grade (77.1% vs 57.1%, P=8.3x10-04), lack of progesterone receptor expression (27.0% vs 15.2%, P=8.8x10-03) and a higher prevalence of estrogen-receptor low expression (ER ≤10%, 25.4% vs 6.5%, P=8.4x10-07). CCNE1-amplified breast cancers were associated with TP53 alterations, high fraction of genome altered, and whole genome doubling events, reflecting marked chromosomal instability. CCNE1 amplification was associated with significantly shorter PFS on first-line THP in HER2+ subtype (8.4 vs 18.0 months, HR 2.33, 95%CI 1.31-4.12, P=3.8×10⁻³), and non-significant trends toward shorter PFS in HR+/HER2- (HR 1.49, 95%CI 0.86-2.58, P=0.16) and triple-negative cancers (HR 1.43, 95%CI 0.95-2.15, P=0.084). CONCLUSIONS: CCNE1 amplification defines a subset of breast cancer characterized by high genomic instability and poor clinical outcomes, supporting its role as a potential biomarker for novel therapeutic strategies in this clinical context.

Clinical Cancer Research
Memorial Sloan Kettering Cancer Center (US), Agostino Gemelli University Polyclinic (IT), AstraZeneca (Singapore) (SG), AstraZeneca (United States) (US), European Institute of Oncology (IT)
Good health and well-being
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon